Provided by Tiger Fintech (Singapore) Pte. Ltd.

Genprex, Inc.

0.3400
-0.0600-15.00%
Pre-market: 0.3370-0.0030-0.88%07:11 EDT
Volume:44.03M
Turnover:20.50M
Market Cap:2.89M
PE:-0.03
High:0.5200
Open:0.4500
Low:0.3300
Close:0.4000
Loading ...

Genprex to Participate at BIO Europe Spring 2025

PR Newswire
·
04 Mar

BRIEF-Genprex Advances Diabetes Program With Addition Of Research Focused On Non-Viral Delivery System

Reuters
·
19 Feb

Genprex announces advancement of diabetes program, strategic collaboration

TIPRANKS
·
19 Feb

Genprex Advances Diabetes Program With Addition of Research Focused on Non-Viral Delivery System

THOMSON REUTERS
·
19 Feb

BRIEF-Genprex Provides Update On Diabetes Gene Therapy Program

Reuters
·
18 Feb

Genprex announces advancement of its diabetes gene therapy program

TIPRANKS
·
18 Feb

Genprex Inc - Forms Wholly-Owned Subsidiary, Convergen Biotech

THOMSON REUTERS
·
18 Feb

Genprex Inc - Signs New Exclusive License Agreement With University of Pittsburgh of Commonwealth System of Higher Education

THOMSON REUTERS
·
18 Feb

Genprex Provides Update on Diabetes Gene Therapy Program

THOMSON REUTERS
·
18 Feb

Genprex Inc - to Seek FDA Guidance for Ind Application in 2025

THOMSON REUTERS
·
18 Feb

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination With Tecentriq® to Treat Small Cell Lung Cancer

THOMSON REUTERS
·
23 Jan

Genprex Inc - Expects to Complete Enrollment of First 25 Patients in H2 2025

THOMSON REUTERS
·
23 Jan

Genprex Advances Cancer Trials and Diabetes Therapy

TipRanks
·
14 Jan

Genprex Completes Phase 1 Dose Escalation in Trial of Reqorsa Gene Therapy to Treat Lung Cancer

MT Newswires Live
·
16 Dec 2024

Genprex receives Safety Review Committee approval to advance Acclaim-3 trial

TIPRANKS
·
16 Dec 2024

Genprex Inc: Results From Phase 1 Dose Escalation Demonstrate Favorable Safety Profile of Reqorsa and Tecentriq in Es-Sclc Patients

THOMSON REUTERS
·
16 Dec 2024